Seragen regulatory update

SRGN submitted a BLA to the FDA for approval of DAB399IL-2 (Interleukin-2 Fusion Protein) to treat recurrent or persistent cutaneous T cell lymphoma (CTCL) despite prior therapy. (Phase III results, s...